Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AEMD > SEC Filings for AEMD > Form 8-K on 15-Apr-2013All Recent SEC Filings

Show all filings for AETHLON MEDICAL INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for AETHLON MEDICAL INC


15-Apr-2013

Entry into a Material Definitive Agreement


ITEM 1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENT

On April 11, 2013, Aethlon Medical, Inc. (the "Company") entered into a subcontract agreement ("Subcontract") with Battelle Memorial Institute ("Battelle"). The Subcontract provides for the Company to provide services under Prime Contract No. HR0011-13-C-0023 ("Prime Contract"), which was awarded to Battelle by the Defense Advanced Research Projects Agency (DARPA) on March 12, 2013. The amount of the prime contract award is $22,830,840. The objective of the Prime Contract is to integrate component technologies developed in a previously established DARPA program entitled Dialysis Like Therapeutics (DLT). The DLT integration program will design, test, and validate an extracorporeal blood purification system to treat sepsis. The program endpoint is the submission of an Investigational Device Exemption (IDE) to the United States Food and Drug Administration.

The Subcontract award from Battelle is a cost-plus contract over the course of approximately four years. Payments to the Company will be dependent upon the time and costs incurred on the Subcontract under the direction of Battelle. The Subcontract is composed of a base period and three option periods to achieve a number of tasks to integrate the DLT component technologies. The right to grant those option periods is also at the discretion of the prime contractor. There can be no assurance that the Company alone, or with third party participants, will achieve the identified tasks under the Subcontract to the satisfaction of Battelle and the government. The Company began work on the Subcontract effective April 1, 2013.

The Company was previously awarded a DLT contract by DARPA to develop two technology components that will be tested in the systems integration program for use within an extracorporeal device to treat sepsis. The first component is a selective therapeutic filtration mechanism to eliminate sepsis precursors, bacterial toxins, viral pathogens, and disease enhancing exosomes from the entire circulatory system. The second component is a blood processing system with an open architecture to deliver a variety of extracorporeal therapies without the need for systemic anticoagulant administration. To date, the Company has achieved eleven milestone goals under this contract and is in year two of that five year contract.

  Add AEMD to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AEMD - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.